PMID- 24833640
OWN - NLM
STAT- MEDLINE
DCOM- 20151123
LR  - 20220408
IS  - 2048-8734 (Electronic)
IS  - 2048-8726 (Linking)
VI  - 4
IP  - 1
DP  - 2015 Feb
TI  - Plasma levels of active Von Willebrand factor are increased in patients with 
      first ST-segment elevation myocardial infarction: a multicenter and multiethnic 
      study.
PG  - 64-74
LID - 10.1177/2048872614534388 [doi]
AB  - AIMS: Von Willebrand factor (VWF), a key player in hemostasis and thrombosis, is 
      released from endothelial cells during inflammation. Upon release, VWF is 
      processed by ADAMTS13 into an inactive conformation. The aim of our study was to 
      investigate whether plasma levels of active VWF, total VWF, ADAMTS13, 
      osteoprotegerin (OPG) and the ratios between VWF and ADAMTS13 are risk factors 
      for first ST-segment elevation myocardial infarction (STEMI). METHODS AND 
      RESULTS: We assessed 1026 patients with confirmed first STEMI and 652 control 
      subjects from China, Italy and Scotland, within six hours after their 
      cardiovascular event. Median plasma levels of total VWF, active VWF, OPG and 
      ratios VWF/ADAMTS13 were increased, while plasma levels of ADAMTS13 were 
      decreased in patients compared to controls. The odds ratio (OR) of STEMI in 
      patients with high plasma levels of active VWF was 2.3 (interquartile range 
      (IQR): 1.8-2.9), total VWF was 1.8 (1.4-2.3), ADAMTS13 was 0.6 (05-0.8), OPG was 
      1.6 (1.2-2.0) and high VWF/ADAMTS13 ratios was 1.5 (1.2-2.0). The OR for total 
      VWF, active VWF and ratios VWF/ADAMTS13 remained significant after adjustment for 
      established risk factors, medical treatment, C-reactive protein, total VWF, 
      ADAMTS13 and OPG. When we adjusted for levels of active VWF, the significance of 
      the OR for VWF and ratios VWF/ADAMTS13 disappeared while the OR for active VWF 
      remained significant. CONCLUSIONS: We found evidence that plasma levels of active 
      VWF are an independent risk factor for first STEMI in patients from three 
      different ethnic groups. Our findings confirm the presence of VWF abnormalities 
      in patients with STEMI and may be used to develop new therapeutic approaches.
CI  - (c) The European Society of Cardiology 2014.
FAU - Rutten, B
AU  - Rutten B
AD  - Laboratory of Clinical Chemistry and Haematology, University Medical Center 
      Utrecht, The Netherlands.
FAU - Maseri, A
AU  - Maseri A
AD  - Heart Care Foundation, Florence, Italy.
FAU - Cianflone, D
AU  - Cianflone D
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Laricchia, A
AU  - Laricchia A
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Cristell, N A
AU  - Cristell NA
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Durante, A
AU  - Durante A
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Spartera, M
AU  - Spartera M
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Ancona, F
AU  - Ancona F
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Limite, L
AU  - Limite L
AD  - Clinical Cardiovascular Biology Centre, Universita Vita-Salute San Raffaele, 
      Italy.
FAU - Hu, D
AU  - Hu D
AD  - The Heart Center, People's Hospital of Peking University, China.
FAU - Li, H
AU  - Li H
AD  - The Heart Center, People's Hospital of Peking University, China.
FAU - Uren, N G
AU  - Uren NG
AD  - Department of Cardiology, Royal Infirmary of Edinburgh, UK.
FAU - de Groot, P G
AU  - de Groot PG
AD  - Laboratory of Clinical Chemistry and Haematology, University Medical Center 
      Utrecht, The Netherlands.
FAU - Mannucci, P M
AU  - Mannucci PM
AD  - A Bianchi Bonomi Hemophilia and Thrombosis Center, Ospedale Maggiore Policlinico, 
      Italy.
FAU - Roest, M
AU  - Roest M
AD  - Laboratory of Clinical Chemistry and Haematology, University Medical Center 
      Utrecht, The Netherlands M.Roest@umcutrecht.nl.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140515
PL  - England
TA  - Eur Heart J Acute Cardiovasc Care
JT  - European heart journal. Acute cardiovascular care
JID - 101591369
RN  - 0 (Biomarkers)
RN  - 0 (Osteoprotegerin)
RN  - 0 (von Willebrand Factor)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.87 (ADAMTS13 Protein)
RN  - EC 3.4.24.87 (ADAMTS13 protein, human)
SB  - IM
MH  - ADAM Proteins/metabolism
MH  - ADAMTS13 Protein
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Case-Control Studies
MH  - China/ethnology
MH  - Female
MH  - Humans
MH  - Italy/ethnology
MH  - Male
MH  - Myocardial Infarction/blood/*diagnosis/ethnology
MH  - Osteoprotegerin/metabolism
MH  - Regression Analysis
MH  - Risk Factors
MH  - Scotland/ethnology
MH  - von Willebrand Factor/*metabolism
OTO - NOTNLM
OT  - ADAMTS13
OT  - Active von Willebrand factor
OT  - ST-segment elevation myocardial infarction
OT  - osteoprotegerin
OT  - risk factors
OT  - von Willebrand factor
EDAT- 2014/05/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/05/17 06:00
PHST- 2014/05/17 06:00 [entrez]
PHST- 2014/05/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 2048872614534388 [pii]
AID - 10.1177/2048872614534388 [doi]
PST - ppublish
SO  - Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):64-74. doi: 
      10.1177/2048872614534388. Epub 2014 May 15.